

## References

1. Kushakovskiy MS. SPb: Foliant. 2004.672p.
2. Feschenko YI, Rekalova OM, Begouleva JB, Kozashuk IA. *Ukr. pulmonologicheskij zhurnal – Ukrainian pulmonological Journal*, 2004.55–59 p. (in Russ).
3. Fogoros RH. A practical guide. – Binom 2009.199 p. (in Russ).
4. Aldershvile J. Early diagnosis of amiodarone induced pulmonary toxicity: are repeated lung function tests of any value? *Ugeskr Laeger* 1996;10,№158 (24):3445–7.
5. Arnon R, Raz I, Chajek-Shaul T. Amiodarone pulmonary toxicity presenting as a solitary lung mass. *Chest* 1998;93:425.
6. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW Jr, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ;ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias – executive summary: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). *Circulation* 2003;108(15):1871–909.
7. Card JW, Racz WJ, Brien JF, Massey TE. Attenuation of amiodarone induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor beta 1 gene expression but not prevention of mitochondrial dysfunction. *J Pharma Coll Exp Ther* 2003;304,(1):277–83.
8. Careful Monitoring Required to Minimise the Damage of Amiodarone Induced Pulmonary Toxicity. *Drug & Ther Perspect* 1998;12(12):14–6.
9. Coudert B, Bailly F, Lombard JN. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. *Chest* 1992;102:1005.
10. Donaldson L, Grant IS, Naysmith MR, Thomas JS. Acute amiodarone-induced lung toxicity. *Intensive Care Med* 1998;24(6):626–30.
11. Donaldson L, Grant IS, Naysmith MR, Thomas JS. Acute amiodarone induced lung toxicity. *Intensive Care Med* 1999;25(2):242–3.
12. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, Heger JJ. Clinical features of amiodarone-induced pulmonary toxicity. *Circulation* 1990;82:51–9.
13. Friedrich M, Hoffmann E, Mitlehner W. Amiodarone induced segmental lung infiltration. Radiologic and computed tomographic aspects. *Radiologe* 1989;29(10):519–22.
14. Handschin AE, Lardinois D, Schneiter D, Bloch K, Weder W. Acute amiodarone-induced pulmonary toxicity following lung resection. *Respiration* 2003;70(3):310–2.

15. Hilleman D, Miller MA, Parker R. Optimal management of amiodarone therapy: efficacy and side effects. *Pharmacother* 1998;18(6)Pt.2:138–45.
16. Jessurun GA, Boersma WG, Crijns HJ. Amiodarone induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. *Drug Saf* 1998;18(5):339–44.
17. Kanji Z, Sunderji R, Gin K. Amiodarone induced pulmonary toxicity. *Pharmacother* 1999;19(12):1463–6.
18. Kaushik S, Hussain A, Clarke P, Lazar HL. Acute pulmonary toxicity after low dose amiodarone therapy. *Ann Thorac Surg* 2001;72(5):1760–1.
19. Roberts-Thompson KC, Kistler PM, Kalman JM. Atrial tachycardia: mechanisms, diagnosis, and management. *Curr Probl Cardiol* 2005;30:529–73.
20. Saoudi N, Cosio F, Waldo A, Chen SA, Iesaka Y, Lesh M, Saksena S, Salerno J, Schoels W. Classification of atrial flutter and regular atrial tachycardia according to electrophysiologic mechanism and anatomic bases: a statement from a joint expert group from the Working Group of Arrhythmias of European Society of Cardiology and North American Society of Pacing and Electrophysiology. *J Cardiovasc Electrophysiol* 2001;12:852–6.